BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Pharm Country

  Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024

  Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in San Diego, CA.

  February 1, 2024

   · 

  5 min read
• Deals

  UCI Health Reaches Definitive Agreement to Acquire Four Southern California Hospitals From Tenet Healthcare Corporation

  The Regents of the University of California, on behalf of the University of California, Irvine, has entered into a definitive agreement with Tenet Healthcare Corporation to acquire Tenet’s Pacific Coast Network.

  February 1, 2024

   · 

  6 min read
• Business

  Labcorp Named One of the World’s Most Admired Companies™ by FORTUNE® Magazine

  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine’s list of the World’s Most Admired Companies™, a recognition of the most respected and reputable companies globally.

  February 1, 2024

   · 

  1 min read
• Business

  Remix Therapeutics Appoints Dominic Reynolds, Ph.D., as Chief Scientific Officer

  Remix Therapeutics today announced the appointment of Dominic Reynolds, Ph.D., as Chief Scientific Officer (CSO).

  February 1, 2024

   · 

  2 min read
• Deals

  Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.

  Numinus Wellness Inc. announces today that it has entered into an agreement to divest its holdings in Alto Neuroscience Inc. (“Alto”), a clinical-stage biopharmaceutical company.

  February 1, 2024

   · 

  3 min read
• Antibe Extends Early Warrant Exercise Incentive Program

  Antibe Therapeutics Inc. is extending the Early Warrant Exercise Incentive Program for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.

  February 1, 2024

   · 

  3 min read
• Drug Development

  Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy

  Aviceda Therapeutics announced today that it has dosed the first patient in Part 2 of the Phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

  February 1, 2024

   · 

  3 min read
• Business

  ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

  Dr. Clarke Joins ZYUS’ Clinical Advisory Committee, Bringing Extensive Expertise in Healthcare and Pain Management.

  February 1, 2024

   · 

  6 min read
• Business

  Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

  Surmodics, Inc. today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending September 30, 2024.

  February 1, 2024

   · 

  21 min read
• Business

  Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

  Healthcare Innovation Catalysts, Inc. announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer.

  February 1, 2024

   · 

  4 min read